163 related articles for article (PubMed ID: 23896709)
21. PAX 2: a novel Müllerian marker for serous papillary carcinomas to differentiate from micropapillary breast carcinoma.
Chivukula M; Dabbs DJ; O'Connor S; Bhargava R
Int J Gynecol Pathol; 2009 Nov; 28(6):570-8. PubMed ID: 19851209
[TBL] [Abstract][Full Text] [Related]
22. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
[TBL] [Abstract][Full Text] [Related]
23. Hobnail-like cells in serous borderline tumor do not represent concomitant incipient clear cell neoplasms.
Ohishi Y; Oda Y; Kurihara S; Kaku T; Yasunaga M; Nishimura I; Okuma E; Kobayashi H; Wake N; Tsuneyoshi M
Hum Pathol; 2009 Aug; 40(8):1168-75. PubMed ID: 19368953
[TBL] [Abstract][Full Text] [Related]
24. Transitional cell-like morphology in ovarian endometrioid carcinoma: morphologic, immunohistochemical, and behavioral features distinguishing it from high-grade serous carcinoma.
Karnezis AN; Aysal A; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2013 Jan; 37(1):24-37. PubMed ID: 23108017
[TBL] [Abstract][Full Text] [Related]
25. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin?
Roh MH; Kindelberger D; Crum CP
Am J Surg Pathol; 2009 Mar; 33(3):376-83. PubMed ID: 19011565
[TBL] [Abstract][Full Text] [Related]
26. Ependymomas of the central nervous system and adult extra-axial ependymomas are morphologically and immunohistochemically distinct--a comparative study with assessment of ovarian carcinomas for expression of glial fibrillary acidic protein.
Idowu MO; Rosenblum MK; Wei XJ; Edgar MA; Soslow RA
Am J Surg Pathol; 2008 May; 32(5):710-8. PubMed ID: 18360284
[TBL] [Abstract][Full Text] [Related]
27. Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis?
Moritani S; Ichihara S; Hasegawa M; Endo T; Oiwa M; Yoshikawa K; Sato Y; Aoyama H; Hayashi T; Kushima R
Hum Pathol; 2008 May; 39(5):666-71. PubMed ID: 18339419
[TBL] [Abstract][Full Text] [Related]
28. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary.
Köbel M; Kalloger SE; Carrick J; Huntsman D; Asad H; Oliva E; Ewanowich CA; Soslow RA; Gilks CB
Am J Surg Pathol; 2009 Jan; 33(1):14-21. PubMed ID: 18830127
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
30. Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry.
Ali RH; Kalloger SE; Santos JL; Swenerton KD; Gilks CB
Int J Gynecol Pathol; 2013 Nov; 32(6):529-35. PubMed ID: 24071867
[TBL] [Abstract][Full Text] [Related]
31. Ovarian transitional cell carcinoma represents a poorly differentiated form of high-grade serous or endometrioid adenocarcinoma.
Takeuchi T; Ohishi Y; Imamura H; Aman M; Shida K; Kobayashi H; Kato K; Oda Y
Am J Surg Pathol; 2013 Jul; 37(7):1091-9. PubMed ID: 23681072
[TBL] [Abstract][Full Text] [Related]
32. High-grade ovarian serous carcinomas: Significant correlation of histologic patterns with IMP3 and E-Cadherin predicting disease recurrence and survival.
Mohanty SK; Tiwari A; Singh C; Walsh C; Chuang F; Kim E; Singh K; Dadmanesh F
Ann Diagn Pathol; 2019 Jun; 40():30-39. PubMed ID: 30921622
[TBL] [Abstract][Full Text] [Related]
33. Serous carcinoma arising from uterine adenomyosis/adenomyotic cyst of the cervical stump: a report of 3 cases.
Lu B; Chen Q; Zhang X; Cheng L
Diagn Pathol; 2016 Jun; 11(1):46. PubMed ID: 27260518
[TBL] [Abstract][Full Text] [Related]
34. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.
Liu JF; Hirsch MS; Lee H; Matulonis UA
Gynecol Oncol; 2009 Dec; 115(3):401-6. PubMed ID: 19796795
[TBL] [Abstract][Full Text] [Related]
35. Serous papillary carcinoma of the endometrium arising from endometrial polyps: a clinical, histological, and immunohistochemical study of 13 cases.
Trahan S; Têtu B; Raymond PE
Hum Pathol; 2005 Dec; 36(12):1316-21. PubMed ID: 16311126
[TBL] [Abstract][Full Text] [Related]
36. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
Karaferic A; Jovanovic D; Jelic S
J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
[TBL] [Abstract][Full Text] [Related]
37. Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology.
Han L; Pansare V; Al-Abbadi M; Husain M; Feng J
Diagn Cytopathol; 2010 May; 38(5):333-6. PubMed ID: 19856421
[TBL] [Abstract][Full Text] [Related]
38. Clinically occult tubal and ovarian high-grade serous carcinomas presenting in uterine samples: diagnostic pitfalls and clues to improve recognition of tumor origin.
Bagby C; Ronnett BM; Yemelyanova A; Maleki Z; Kuhn E; Vang R
Int J Gynecol Pathol; 2013 Sep; 32(5):433-43. PubMed ID: 23896706
[TBL] [Abstract][Full Text] [Related]
39. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
[TBL] [Abstract][Full Text] [Related]
40. WT1 expression in the female genital tract.
Bárcena C; Oliva E
Adv Anat Pathol; 2011 Nov; 18(6):454-65. PubMed ID: 21993272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]